Anavex Life Sciences Corp (AVXL)

[F1ash]

Any thoughts, clues, explanations on why AVXL sp continues to waffle-edge downward or what ever the technical term is for what we have seen since last trial start PR? I am open to rational conspiracy theories as explanation.

Do you think it’s helpful that Anavex has no debt and cash in the bank? Wouldn’t it be a good idea to keep it that way? Generally speaking wouldn’t you expect expenses to raise significantly with 3 1/2 clinical trials running compared to just 1? If you were running the company and wanted to use the Cantor agreement to add to the cash account, when would you do that? Would you time the tapping to coincide with a positive PR release? I would. Increased volume is needed imho.